PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|February 5, 2020
West to Showcase New Products at Pharmapack 2020
Author(s)Pharmaceutical Technology Editors
West Pharmaceutical Services will be showcasing various new pharmaceutical containment and closure offerings at Pharmapack from Feb. 5–6 in Paris, France.
Advertisement
West Pharmaceutical Services, an injectable drug administration company based in Exton, PA, announced it will be showcasing various new pharmaceutical containment and closure offerings at Pharmapack from Feb. 5–6 in Paris, France.
According to a company press release, the new products include:
- AccelTRA components program. This includes two line extensions, the AccelTRA and the AccelTRA Select EU. Also to be featured will be 13-mm and 20-mm serum and lyo stoppers in eight configurations and 1–3-mL plungers for generics customers.
- Flip-Off CCS Seal. Formulated to provide users with a ready-to-use sterile capping product, this seal maintains container closure integrity and supports a useful customer experience.
- Ready Pack system. Developed in collaboration with Schott, this system combines West and Schott products on a small quality basis.
The company will also host two presentations during the conference. Fran DeGrazio, vice-president, Scientific Affairs and Technical Services at West, will present on “Understanding the Complexities of Delivering a Biologic Drug to the Market” during the main Pharmapack session on biologics on Feb. 6 at 10:05 a.m. CEST, and Nico Brandes, director, Market Development, Innovation, and Technology at West will host a Learning Lab session entitled, “Design with the End in Mind: Patient-Centric Innovations in Containment and Delivery,” on Feb. 6 at 11:30 a.m. CEST.
“West’s priority is to help customers simplify their journey, whether through new products or by helping mitigate risks in the drug development process to accelerate speed to market in today’s ever-evolving, complex industry and global regulatory environment,” said DeGrazio in the company press release. “We have deep knowledge of navigating the nuances of biologic drugs and delivery systems even at the earliest stages, including quality systems, design controls, and risk management frameworks. By keeping a lens on the unique interface between a drug, its primary package and device, we support our customers with smart integrated solutions from end to end that help them meet, if not exceed, industry standards.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement